Nrdp1-mediated ErbB3 degradation inhibits glioma cell migration and invasion by reducing cytoplasmic localization of p27(Kip1). (Q38862374)

7 September 2017

Nrdp1-mediated ErbB3 degradation inhibits glioma cell migration and invasion by reducing cytoplasmic localization of p27(Kip1). (English)

1 reference

7 September 2017

Hengliang Shi

1

1 reference

7 September 2017

Hui Gong

2

1 reference

7 September 2017

Kuan Cao

3

1 reference

7 September 2017

Shenshan Zou

4

1 reference

7 September 2017

Bingxin Zhu

5

1 reference

7 September 2017

Hanmo Bao

6

1 reference

7 September 2017

Yuxuan Wu

7

1 reference

7 September 2017

Yong Gao

8

1 reference

7 September 2017

Yuan Tang

9

1 reference

7 September 2017

Rutong Yu

10

1 reference

7 September 2017

19 June 2015

1 reference

Journal of Neuro-Oncology

7 September 2017

1 reference

7 September 2017

124

1 reference

7 September 2017

3

1 reference

7 September 2017

357-364

1 reference

https://scigraph.springernature.com/pub.10.1007/s11060-015-1851-9

7 September 2017

0 references

cites work

Malignant gliomas in adults

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1851-9

Recent advances in therapy for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1851-9

The phosphoinositide 3-kinase signaling pathway as a therapeutic target in grade IV brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1851-9

Neuregulin and ErbB receptor signaling pathways in the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1851-9

Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1851-9

ErbBs in mammary development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1851-9

Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1851-9

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1851-9

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1851-9

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1851-9

Regulation of ERBB3/HER3 signaling in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1851-9

Nrdp1/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1851-9

Nrdp1 inhibits growth of colorectal cancer cells by nuclear retention of p27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1851-9

Lower expression of Nrdp1 in human glioma contributes tumor progression by reducing apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1851-9

Quantity control of the ErbB3 receptor tyrosine kinase at the endoplasmic reticulum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1851-9

Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1851-9

Targeting ErbB receptors in high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1851-9

The ERBB network: at last, cancer therapy meets systems biology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1851-9

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1851-9

Uncoupling of PI3K from ErbB3 impairs mammary gland development but does not impact on ErbB2-induced mammary tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1851-9

Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1851-9

PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1851-9

PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1851-9

Structural features that specify tyrosine kinase activity deduced from homology modeling of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1851-9

Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1851-9

Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1851-9

Novel p27(kip1) C-terminal scatter domain mediates Rac-dependent cell migration independent of cell cycle arrest functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1851-9

p27Kip1 modulates cell migration through the regulation of RhoA activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1851-9

10.1007/S11060-015-1851-9

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

7 September 2017

0 references

1 reference